263 related articles for article (PubMed ID: 23259626)
1. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
Simsek I
Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
[TBL] [Abstract][Full Text] [Related]
2. TNF inhibitors for rheumatoid arthritis - a year in review.
Simsek I
Bull NYU Hosp Jt Dis; 2011; 69(3):220-4. PubMed ID: 22035432
[TBL] [Abstract][Full Text] [Related]
3. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
4. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological approaches in immuno-rhumatology].
Fabre S
Therapie; 2011; 66(5):397-404. PubMed ID: 22031683
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
8. The need for personalised medicine for rheumatoid arthritis.
Isaacs JD; Ferraccioli G
Ann Rheum Dis; 2011 Jan; 70(1):4-7. PubMed ID: 21068091
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
10. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
11. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
13. State-of-the-art: rheumatoid arthritis.
McInnes IB; O'Dell JR
Ann Rheum Dis; 2010 Nov; 69(11):1898-906. PubMed ID: 20959326
[TBL] [Abstract][Full Text] [Related]
14. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B; Rhodus NL; Patel K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis--efficacy evaluation, adverse effect detection, and prediction of clinical response].
Yamamura M
Nihon Rinsho; 2007 Jul; 65(7):1269-75. PubMed ID: 17642242
[TBL] [Abstract][Full Text] [Related]
17. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
Ingegnoli F; Favalli EG; Meroni PL
Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
[TBL] [Abstract][Full Text] [Related]
18. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
Gómez-Reino JJ; Rodríguez-Lozano C; Campos-Fernández C; Montoro M; Descalzo MÁ; Carmona L;
Ann Rheum Dis; 2012 Mar; 71(3):382-5. PubMed ID: 21998116
[TBL] [Abstract][Full Text] [Related]
19. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
20. T-cell agents in the treatment of rheumatoid arthritis - 2012 update.
Solomon GE
Bull NYU Hosp Jt Dis; 2012; 70(3):191-4. PubMed ID: 23259627
[No Abstract] [Full Text] [Related]
[Next] [New Search]